Published in Bioorg Med Chem Lett on February 17, 2011
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther (2013) 0.87
Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy. Clin Cancer Res (2013) 0.85
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study. Bioorg Med Chem (2012) 0.83
In Vitro and In Vivo Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis. Antimicrob Agents Chemother (2016) 0.79
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study. J Med Chem (2016) 0.76
A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβ. Immunol Lett (2015) 0.75
Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol (2010) 3.01
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun (2007) 1.44
Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ (2010) 1.32
Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem (2010) 1.32
Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem (2006) 1.25
High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Anal Biochem (2006) 1.20
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem (2007) 1.18
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol (2009) 1.02
Structural characterization of BRCT-tetrapeptide binding interactions. Biochem Biophys Res Commun (2010) 1.01
High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem (2010) 0.89
Fluorescence-enhanced europium-diethylenetriaminepentaacetic (DTPA)-monoamide complexes for the assessment of renal function. J Med Chem (2008) 0.87
Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors. Bioorg Med Chem Lett (2007) 0.86
The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation. Curr Drug Discov Technol (2009) 0.85
One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation. Bioorg Med Chem (2006) 0.85
Synthesis and biological activities of pyrazolo[3,4-g]quinoxaline derivatives. Eur J Med Chem (2010) 0.82
ACTION OF QUINACILLIN ON STAPHYLOCOCCUS AUREUS. Nature (1964) 0.81
Synthesis and peptidyl-prolyl isomerase inhibitory activity of quinoxalines as ligands of cyclophilin A. Chem Pharm Bull (Tokyo) (2006) 0.80
A synopsis of recent developments in antiglaucoma drugs. J Ocul Pharmacol (1985) 0.79
A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev (2007) 1.97
Hydrogen therapy reduces apoptosis in neonatal hypoxia-ischemia rat model. Neurosci Lett (2008) 1.71
Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. Brain Res (2008) 1.60
Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res (2003) 1.47
Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther (2008) 1.43
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem (2010) 1.32
Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release (2005) 1.31
Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 1.27
High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Anal Biochem (2006) 1.20
RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses. Proc Natl Acad Sci U S A (2011) 1.19
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem (2007) 1.18
Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. J Am Chem Soc (2007) 1.14
Bax contains two functional mitochondrial targeting sequences and translocates to mitochondria in a conformational change- and homo-oligomerization-driven process. J Biol Chem (2009) 1.10
The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo. PLoS One (2013) 1.08
Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm (2006) 1.05
Changes in reproductive physiology of lactating dairy cows due to elevated steroid metabolism. Theriogenology (2005) 1.04
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget (2011) 1.01
Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest (2008) 1.01
Structural characterization of BRCT-tetrapeptide binding interactions. Biochem Biophys Res Commun (2010) 1.01
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther (2011) 1.00
Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer (2009) 0.95
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol (2006) 0.94
Sox2 uses multiple domains to associate with proteins present in Sox2-protein complexes. PLoS One (2010) 0.94
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J Control Release (2008) 0.92
Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res (2007) 0.92
Pulse design for broadband correlation NMR spectroscopy by multi-rotating frames. J Biomol NMR (2013) 0.91
Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorg Med Chem Lett (2011) 0.90
The methodology used to measure differential gene expression affects the outcome. J Biomol Tech (2007) 0.90
High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem (2010) 0.89
Pivotal role of inosine triphosphate pyrophosphatase in maintaining genome stability and the prevention of apoptosis in human cells. PLoS One (2012) 0.89
Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1. J Med Chem (2011) 0.89
Identification of the DNA-Binding Domains of Human Replication Protein A That Recognize G-Quadruplex DNA. J Nucleic Acids (2011) 0.88
Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat (2012) 0.88
Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. ACS Med Chem Lett (2011) 0.87
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther (2013) 0.87
Active Bax and Bak are functional holins. Genes Dev (2011) 0.87
Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1. J Comput Aided Mol Des (2011) 0.85
Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. J Med Chem (2012) 0.85
Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins. Biochem Anal Biochem (2012) 0.85
Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy. Clin Cancer Res (2013) 0.85
The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides. Sci Rep (2013) 0.85
Axial SiGe heteronanowire tunneling field-effect transistors. Nano Lett (2012) 0.85
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. J Med Chem (2014) 0.84
BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci (2005) 0.84
Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett (2004) 0.84
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study. Bioorg Med Chem (2012) 0.83
High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity. Anal Biochem (2013) 0.82
Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS. Biomed Chromatogr (2013) 0.82
Lineage diversification and historical demography of a montane bird Garrulax elliotii--implications for the Pleistocene evolutionary history of the eastern Himalayas. BMC Evol Biol (2011) 0.82
The heparin binding motif of endostatin mediates its interaction with receptor nucleolin. Biochemistry (2009) 0.81
Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase. J Med Chem (2013) 0.80
Helium preconditioning attenuates hypoxia/ischemia-induced injury in the developing brain. Brain Res (2010) 0.79
Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein. Biochem Biophys Res Commun (2005) 0.79
RNA interference-mediated inhibition of hepatocyte nuclear factor 1alpha identifies target genes. Biochim Biophys Acta (2008) 0.78
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg Med Chem Lett (2004) 0.78
[Effect of bizhongxiao decotion on TNF-alpha and interleukin-1beta in plasma of rats with C II-induced rheumatoid arthritis]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2004) 0.78
Face selective reduction of the exocyclic double bond in isatin derived spirocyclic lactones. Org Biomol Chem (2012) 0.77
Protein-protein interactions as therapeutic targets in neuropsychopharmacology. Neuropsychopharmacology (2009) 0.77
An HPLC method for the determination and pharmacokinetic study of cinnamic acid in the plasma of rats having taken the traditional Chinese medicinal preparation Ling-Gui-Zhu-Gan decoction. J Chromatogr Sci (2002) 0.77
Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study. J Med Chem (2016) 0.76
Synthesis of conformationally constrained lysine analogues. J Org Chem (2006) 0.76
Beyond the frog: the evolution of homology models of human IKKβ. Bioorg Med Chem Lett (2011) 0.75
Irreversible binding of an anticancer compound (BI-94) to plasma proteins. Xenobiotica (2015) 0.75
Synthesis of unnatural amino acid derivatives via palladium catalyzed 1,4 addition of boronic acids. Tetrahedron Lett (2010) 0.75
Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides. Bioorg Med Chem Lett (2007) 0.75
Effect of Bizhongxiao Decotion (BZXD) on Some Cytokines in Plasma of Rats with CII-induced Rheumatoid Arthritis. Int J Biomed Sci (2005) 0.75
[The influence of endotracheal tube cuff pressures to PEEP values in mechanical ventilated patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue (2009) 0.75
[Impact of preservation of distal prostatic capsula and seminal vesicle on functions of orthotopic ideal neobladder and erectile function of bladder cancer patients]. Ai Zheng (2008) 0.75
Osteopontin as a potential therapeutic target for ischemic stroke. Curr Drug Deliv (2016) 0.75
Comparative Study on the Roles of the Number of Accelerations and Rotation Angle in the Treatment Maneuvers for Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo. ORL J Otorhinolaryngol Relat Spec (2015) 0.75
827 Predictors of Successful Extubation in Neurosurgical Patients. Neurosurgery (2000) 0.75
[Effects of sampling plot number on tree species distribution prediction under climate change]. Ying Yong Sheng Tai Xue Bao (2013) 0.75
[Establishment of standard forest fuel models for Fenglin Natural Reserve, Heilongjiang Province, China]. Ying Yong Sheng Tai Xue Bao (2012) 0.75
The isolation, identification and determination of dehydrotumulosic acid in Poria cocos. Anal Sci (2002) 0.75
High-performance liquid chromatographic method for the determination and pharmacokinetic study of dehydrotumulosic acid in the plasma of rats having taken the traditional chinese medicinal preparation Ling-Gui-Zhu-Gan decoction. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75
[Construction and evaluation of the epidemiological injury criteria based on the combination of 'Hurt' and 'Harm']. Nan Fang Yi Ke Da Xue Xue Bao (2016) 0.75
Decontamination of organochlorine pesticides in Radix codonopsis by supercritical fluid extractions and determination by gas chromatography. Biomed Chromatogr (2006) 0.75
[Influence of fire disturbance on aboveground deadwood debris carbon storage in Huzhong forest region of Great Xing'an Mountains, Northeast China]. Ying Yong Sheng Tai Xue Bao (2015) 0.75
Sediment Profile and Fluxes of Mercury and Methyl Mercury in Weihe Watershed in Henan, China. Bull Environ Contam Toxicol (2015) 0.75
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) (2017) 0.75